GlassScriptPhysician profile
Chloe Asaker
NPI 1336858752
$3,563.89
in general payments reported to CMS, 2019-2025
38 companies · $919 in 2025
The $919 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $183 · 2023: $1,344 · 2024: $1,118 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $352.61 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $315.22 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $251.18 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $221.66 | 2023-2025 | Gemtesa |
| Abbvie INC. | $186.91 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $182.40 | 2023-2025 | Rexulti |
| Pfizer INC. | $170.38 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $153.20 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $115.65 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $114.63 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $111.85 | 2022-2023 | |
| Medtronic, INC. | $109.83 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Exact Sciences Corporation | $105.66 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $101.43 | 2023-2024 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $83.14 | 2023 | Camzyos, Eliquis |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $81.41 | 2024 | Purified Cortrophin Gel |
| Shield Therapeutics INC | $76.94 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.39 | 2023 | Xifaxan |
| Novo Nordisk INC | $69.68 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Mylan Specialty L.P. | $69.50 | 2023 | Yupelri |
| Indivior INC. | $59.13 | 2023 | Perseris |
| Amgen INC. | $49.61 | 2024 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $48.81 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.42 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $42.49 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi Pasteur INC. | $41.80 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.84 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Verona Pharma, INC. | $37.27 | 2025 | Ohtuvayre |
| Eisai INC. | $35.20 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $34.02 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.40 | 2025 | Jardiance |
| Dexcom, INC. | $27.08 | 2025 | Dexcom G6 Transmitter |
| Covis Pharma Gmbh | $25.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.44 | 2023 | Givlaari |
| Daiichi Sankyo INC. | $20.43 | 2023 | Injectafer |
| Seqirus USA INC | $20.42 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Cequr Corporation | $18.84 | 2025 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $17.21 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Asaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.